Immuron Ltd ADR logo

Immuron Ltd ADR(IMRN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.88
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for IMRN

11/13/2026: IMRN (1-star) is currently NOT-A-BUY. Pass it for now.

Immuron Ltd ADR is a micro-cap biopharmaceutical company that develops oral immunotherapies using bovine colostrum antibody platforms. Its primary business strength lies in its commercialized over-the-counter products, such as Travelan, which generate steady baseline revenues and support ongoing operations. The main growth opportunity centers on expanding global retail distribution and securing strategic development partners for its clinical pipeline targeting gastrointestinal infections. Key risks include micro-cap price volatility, ongoing operating losses, and heavy reliance on travel health product sales. The stock suits speculative growth investors willing to tolerate high volatility while monitoring clinical partnership updates and quarterly sales momentum.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile commercial revenues are growing, the company remains a micro-cap entity with modest top-line scale.
Momentum investorStrong fit while signal remains positiveMomentum fit is conditional on a positive Upturn signal and news-driven volume breakouts.
Value investorWeak fitEarnings remain negative as capital is allocated toward pipeline development, limiting traditional value metrics.
Dividend investorWeak fitImmuron does not pay dividends, focusing instead on commercialization and clinical development.
Low-risk investorWeak fitMicro-cap biotechnology stocks carry high price volatility and execution risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighLow trading liquidity and small market capitalization can trigger sharp price swings.
Valuation riskMedium / highValuation is heavily dependent on future commercial adoption and clinical partnership potential.
Competition risk (specialty biopharma & OTC alternatives)MediumThe company competes against established alternative remedies and well-funded health supplement brands.
Business qualityMediumProprietary products provide a defensible niche, but overall operational scale remains small.
Dividend incomeLow / noneNo dividend is paid, offering zero income return for investors.
Execution riskHighSuccess depends on executing international sales strategies and securing lucrative development partnerships.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 7.06M USD
Price to earnings Ratio -
1Y Target Price 2.56
Price to earnings Ratio -
1Y Target Price 2.56
Volume (30-day avg) 25.9K shares
Beta 0.47
52 Weeks Range 0.68 - 1.99
Updated Date 11/15/2026
52 Weeks Range 0.68 - 1.99
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.34

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -37.62%
Avg. Invested days 34
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
IMRN receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
IMRN has moderate overall fundamentals (3 stars), with moderate financial health, solid growth momentum, and moderate ownership. In FY2026 versus FY2025, solid earnings growth (+28.0%) is partially offset by weak cash generation (FCF margin -39.8%), moderate revenue growth (+3.5%), weak profitability (net margin -49.8%).

Financial Health Rating

★★★★★
IMRN's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 86.0%). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is IMRN's strongest growth driver at +51.1% FY2026 versus FY2025 (strong, 5 stars). By comparison, earnings growth (+28.0%, solid) is also solid, while revenue growth (+3.5%, moderate) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 2.0% (soft) and 85.2% of outstanding shares are publicly tradable (strong). Insider ownership is only 0.28%, which materially reduces the ownership score.

Top 5 Institutional Investors

Citadel Advisors Llc 0.53%
HRT FINANCIAL LLC 0.26%
BNP Paribas Arbitrage, SA 0.06%
Rhumbline Advisers 0.05%
Morgan Stanley - Brokerage Accounts 0.02%

Unit Economics (Per $1K Revenue)

★★★★★
IMRN generates approximately $645 of gross profit, $-614 of operating income, and $-398 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 13.98%

Quantitative Style Profile

★★★★★
IMRN has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Hyper-immune Products (Global OTC Sales)Revenues generated from commercial over-the-counter brands such as Travelan, PROIBS, and Protectyn across Australia, North America, and international distributors.This is the core engine generating tangible cash flow through everyday retail purchases of travel health and gut care items.
Research and Development Grants & PartnershipsPotential collaborative research funding, milestone payments, or licensing deals associated with clinical pipelines like IMM-124E and IMM-529.Future upside could be unlocked if major pharmaceutical partners step in to co-develop or license their clinical drug candidates.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 2.10M
Price to Sales(TTM) 0.92
Enterprise Value 2.10M
Price to Sales(TTM) 0.92
Enterprise Value to Revenue 0.4
Enterprise Value to EBITDA 0.77
Shares Outstanding 8.07M
Shares Floating 6.87M
Shares Outstanding 8.07M
Shares Floating 6.87M
Percent Insiders 0.28
Percent Institutions 2.02

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.